Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05853887 · ClinicalTrials.gov registry record · NA
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
A NA study of Non Small Cell Lung Cancer Metastatic and Non-Squamous Non-Small Cell Neoplasm of Lung, sponsored by Charu Aggarwal.
- Active
- Registry status
- NA
- Development phase
- 260
- Enrollment target
- 6
- Study locations
NCT05853887: Active NA study of Non Small Cell Lung Cancer Metastatic and Non-Squamous Non-Small Cell Neoplasm of Lung, sponsored by Charu Aggarwal.
NCT05853887 is a NA study of Non Small Cell Lung Cancer Metastatic and Non-Squamous Non-Small Cell Neoplasm of Lung that is active but no longer recruiting, run by Charu Aggarwal. The registered enrollment target is 260 participants, below the 420-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (38% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05853887, a NA study of Non Small Cell Lung Cancer Metastatic and Non-Squamous Non-Small Cell Neoplasm of Lung, is active but no longer recruiting, sponsored by Charu Aggarwal.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 260 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.
Primary Outcome
Were comprehensive molecular test results available prior to initiation of 1L therapy? (Yes/No)
Conditions Studied
Interventions
- BEHAVIORAL iNUDGE
Study Locations (6)
New Jersey
- Penn Medicine Cherry Hill - Cherry Hill
- Penn Medicine Princeton Health - Plainsboro
- Penn Medicine Washington Township - Sewell
- Penn Medicine Voorhees - Voorhees Township
Pennsylvania
- Penn Medicine Lancaster General Health - Lancaster
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT05853887 still lists
NCT05853887 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 420-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (38% lower).
The record links to 3 conditions, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which iNUDGE is the first listed.
NCT05853887 lists 6 locations in 2 states (New Jersey, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05853887 about?
NCT05853887 is a clinical study titled "Liquid Biopsy Based NGS in Newly Diagnosed NSCLC". This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available ...
What is the current status of trial NCT05853887?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 260 participants. The study started on 2023-06-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05853887 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic, Non-Squamous Non-Small Cell Neoplasm of Lung, Newly Diagnosed NSCLC.
What interventions are being tested in trial NCT05853887?
The interventions under investigation include: iNUDGE (BEHAVIORAL).
Who is sponsoring clinical trial NCT05853887?
This trial is sponsored by Charu Aggarwal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05853887 being conducted?
This trial has 6 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Small Cell Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05853887's enrollment target sits among peer trials
260 6th of 16 higher than 11 of 16 other Non Small Cell Lung Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non Small Cell Lung Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI